Exhibit 99.1 Ionis reports fourth quarter and full year 2024 financial results - First independent launch underway following TRYNGOLZATM approval - - Second independent launch on track with donidalorsen PDUFA August 21, 2025 - - WAINUATM U.S. launch delivering accelerating sequential growth - - Ionis exceeds 2024 financial guidance and provides full year 2025 guidance - CARLSBAD, Calif., February 19, 2025 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the f ...

For the quarter ended December 2024, Ionis Pharmaceuticals (IONS) reported revenue of $227 million, down 30.2% over the same period last year. EPS came in at -$0.66, compared to -$0.06 in the year-ago quarter.The reported revenue represents a surprise of +65.19% over the Zacks Consensus Estimate of $137.42 million. With the consensus EPS estimate being -$1.12, the EPS surprise was +41.07%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectation ...

Core Viewpoint - Ionis Pharmaceuticals is expected to report a significant quarterly loss and a substantial decline in revenues compared to the previous year [1] Financial Performance - Analysts predict a quarterly loss of $1.12 per share, reflecting a decline of 1766.7% year-over-year [1] - Revenues are forecasted to be $137.47 million, representing a year-over-year decrease of 57.7% [1] Earnings Estimates Revisions - Over the last 30 days, there has been an upward revision of 3.7% in the consensus EPS estimate for the quarter [2] - Revisions to earnings estimates are crucial indicators for predicting potential investor actions regarding the stock [3] Revenue Breakdown - Revenue from Spinraza royalties is estimated to reach $60.73 million, indicating a year-over-year change of -2% [5] - Licensing and royalty revenue is projected at $5.23 million, reflecting a year-over-year change of -34.7% [5] - Total commercial revenue is estimated at $80.55 million, showing a change of +2% from the prior-year quarter [6] - Revenue from Tegsedi and Waylivra is expected to be $7.06 million, indicating a change of -21.6% from the prior-year quarter [6] - Collaborative agreement revenue is projected at $43.79 million, reflecting a year-over-year change of -75.5% [7] Market Performance - Shares of Ionis Pharmaceuticals have experienced a change of -1.2% in the past month, compared to a +4.7% move of the Zacks S&P 500 composite [7] - The company holds a Zacks Rank 3 (Hold), indicating it is expected to mirror overall market performance in the near future [7]

– Accelerating value creation with numerous commercial, regulatory and pipeline milestones –– Ionis outlines clear path to sustained positive cash flow –CARLSBAD, Calif., Jan. 13, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2024 achievements and previewed important milestones expected in 2025. Ionis will provide a business update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15 at 10:30am PT; the presentation is a ...

Portfolio Updates and Anticipated Milestones - Praxis has three blockbuster programs in late-stage development, with potential for four product launches between 2026 and 2028 [1] - The Essential3 program for ulixacaltamide in essential tremor (ET) includes two Phase 3 studies, with over 100,000 patients showing interest in participating since recruitment began in November 2023 [2] - Relutrigine is being evaluated in the EMBOLD study for developmental and epileptic encephalopathies (DEEs), with plans for the EMERALD study in a broader patient population [3] - Praxis shared an update at the 2024 AES Annual Meeting for an emergency use patient who achieved extended benefit after receiving relutrigine [4] - Ulixacaltamide is a highly selective small molecule inhibitor of T-type calcium channels, currently in late-stage development for essential tremor [5] - Praxis has completed discussions with global regulatory agencies to harmonize a registrational study design for elsunersen, with trial design and timelines expected in Q1 2025 [6] - UCB exercised its option to in-license global development and commercialization rights for a KCNT1 small molecule candidate, with Praxis eligible for up to $100 million in milestone payments and tiered royalties [6] - Praxis is on track to nominate development candidates for its early-stage ASO therapeutic initiatives in 2025, including PRAX-080, PRAX-090, and PRAX-100 [6] Clinical Trial Progress and Results - Vormatrigine demonstrated strong competitive differentiation in Phase 1 studies, with full results to be shared at an upcoming medical conference [10] - The EMPOWER observational study has enrolled over 2,000 patients, with early results shared at the 2024 AES Annual Meeting [10] - The RADIANT Phase 2 study for focal onset seizures (FOS) and generalized epilepsy is enrolling patients, with topline results expected in H1 2025 [10] - The POWER1 Phase 2/3 registrational study for treatment-resistant FOS is progressing, with topline results anticipated in H2 2025 [10] - Relutrigine showed a 46% placebo-adjusted reduction in monthly motor seizures in the EMBOLD study, with 77% reduction in motor seizures for patients continuing into the open-label extension [17] - Over 30% of patients achieved seizure freedom status while on relutrigine, with a median of 46 days of seizure freedom compared to 3 days at baseline [17] Regulatory and Commercial Developments - Praxis anticipates filing the NDA for ulixacaltamide in 2025, following positive results from the Essential3 program [9] - The company plans to re-initiate a study of ulixacaltamide in Parkinson's disease, addressing unmet needs for non-dopaminergic treatment options [9] - Praxis received a third rare pediatric drug designation (RPDD) for relutrigine in Dravet Syndrome, in addition to previous designations for SCN2A and SCN8A DEEs [17] - The company expects to initiate the pivotal trial for elsunersen in H1 2025, following regulatory feedback [8] Financial and Strategic Outlook - Praxis has a cash and investment position of approximately $470 million at the end of 2024, supporting a runway into 2028 [15] - The company is well-positioned for a readout-rich 2025, with results anticipated for ulixacaltamide, vormatrigine, and relutrigine, as well as regulatory submissions [8] - Praxis plans to provide a thorough update across its portfolio at the Investor R&D Day in Q2 2025 [8]

CARLSBAD, Calif., Jan. 8, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. PT on Wednesday, January 15, 2025. A live webcast of the presentation can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events. A replay will be available on the Ionis website within 48 hours and will be archiv ...

Shares of Ionis Pharmaceuticals (IONS) rose nearly 5% in after-market trading on Thursday after the FDA approved its RNA-targeted therapy, olezarsen, in adults with familial chylomicronemia syndrome (FCS). The drug will be marketed under the trade name Tryngolza.The FDA’s nod to Tryngolza makes it the first approved treatment for FCS in the country. The drug’s commercial launch is part of management's broad strategy to deliver a steady flow of wholly-owned medicines to patients. Besides being Ionis’ first w ...

TRYNGOLZA shown to significantly reduce triglycerides and substantially reduce acute pancreatitis events in adults with FCS; a rare, highly debilitating and life-threatening disease Indicated for adults with FCS regardless of genetically or clinically confirmed diagnosis  TRYNGOLZA is the first of four independent launches planned over the next three years, pending approvals Ionis to host webcast today at 6:45pm ET CARLSBAD, Calif., Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) ...

Ionis Pharmaceuticals (IONS) closed the last trading session at $38.26, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $59.65 indicates a 55.9% upside potential.The average comprises 20 short-term price targets ranging from a low of $37 to a high of $77, with a standard deviation of $10.76. While the lowest estimate indicates a decline of 3.3% from the current price l ...

Ionis Pharmaceuticals (IONS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a chan ...